Fig. 3
From: Comparison of 18F-FDG and 68Ga-DOTA-IBA in detecting bone metastases: a lesion-basis study
Images of a 69-year-old man diagnosed with prostate carcinoma who had a history of endocrine therapy for 2 years. (a) The maximum intensity projection (MIP) image of 18F-FDG showed moderate radiotracer uptake in a thoracic vertebra. (e) The maximum intensity projection (MIP) image of 68Ga-DOTA-IBA demonstrated more lesions in the cervical vertebra and pelvis. (b) An osteoblastic lesion in the C3 vertebra right attachment (curved arrows) was negative on 18F-FDG (SUVmax=2.0) and positive on 68Ga-DOTA-IBA (SUVmax=8.7). (c) Another osteoblastic lesion in the T10 vertebra left side (arrowheads) was both positive on 18F-FDG (SUVmax=5.2) and positive on 68Ga-DOTA-IBA (SUVmax=35.0). (d) Osteoblastic lesions in bilateral ilium (dotted arrows and arrows) were negative on 18F-FDG (left: SUVmax=1.4, right: SUVmax=1.6) and positive on 68Ga-DOTA-IBA (left: SUVmax=7.6, right: SUVmax=8.7). Follow-up imaging 3 months later confirmed the presence of these bone metastases. 68Ga-DOTA-IBA, gallium 68 (68Ga)-labeled DOTA-conjugate ibandronic acid; 18F-FDG, fluorine 18 (18F)-labeled fluorodeoxyglucose.
